Navigating First-Line Therapy Choices in Advanced Melanoma: Evidence, Patient Factors, and Shared Decision-Making.
7:00 – 8:00 PM EST
Learning Objectives
- Review current evidence and clinical guidelines for first-line therapy options in advanced melanoma.
- Evaluate key patient-specific factors (e.g., tumor characteristics, comorbidities, genetic markers, and performance status) that influence treatment selection.
- Discuss the role of shared decision-making in aligning treatment plans with patient values, preferences, and quality-of-life considerations.
- Apply evidence-based strategies to optimize individualized care in the first-line treatment setting.
Why Attend?
Gain the latest insights on selecting the optimal first-line therapy for advanced melanoma. Learn how to integrate evolving evidence, patient-specific factors, and shared decision-making to deliver personalized, evidence-based care that improves outcomes.
Event Co-Chairs
Megan Mahoney
MD, FRCPC
Dr. Meghan Mahoney is a Medical Oncologist at the Arthur JE Child Comprehensive Cancer Centre in Calgary where she has been treating GU & Cutaneous malignancies since starting her career there in October 2024.
She completed her internal medicine residency and medical oncology training at Memorial University in her home province of Newfoundland. Her academic pursuits in medicine were preceded by a masters in applied social psychology which she completed at MUN & Deakin University in Melbourne, Australia.
Following her medical oncology residency, she went on to pursue a fellowship in Genitourinary and Cutaneous malignancies at Princess Margaret Hospital in Toronto which she finished in September 2024, just before moving to Calgary to assume her current role. Her research interests include adoptive cellular therapies, organ preservation, clinical trial reform equitable access to care. She is excited to establish and build her career as an oncologist and clinician scientist in Calgary at the AJCCC .
Chloé Béland
MD, FRCPC
Dr. Chloé Béland is a medical oncologist and hematologist at the CHU de Québec, Université Laval. She did her fellowship in melanoma at the Royal Marsden Hospital and in translational research at the Francis Crick Institute both in London (UK). Her principal clinical and research interests are in melanoma and immunotherapy. She is also part of the phase 1 research unit at he CHU de Québec.
This session is part of a multi-channel educational series aimed at improving clinical confidence and patient care in the era of ALK inhibitor therapy
This program has been made possible through unrestricted support from BMS.
Register Now
Login to Access Registration
Webinar registration is open for existing members. Login to access registration or create your free membership here.
